

Slide 1 Slide 2





Slide 3 Slide 4



Disclosures

•With respect to this course, I have no relevant financial relationships to declare.

Slide 5 Slide 6





Slide 7 Slide 8


The Eye in Systemic Disease


- Inflammatory
- · Infectious
- Vascular
- Endocrine
- Neurologic
- · Collagen-vascular
- · Neoplastic







Slide 9 Slide 10






Slide 11 Slide 12





Slide 13 Slide 14



Epidemics and Other Major Public Health Challenges



Obesity/Excess Weight Smoking Age-related Eye Disease


Slide 15 Slide 16




Diabesity

- M______ S____ is characterized by central (abdominal) obesity, dyslipidemia, raised blood pressure, and insulin resistance.
- · "Diabesity"
 - Up to 97% of type 2 caused by excessive weight
 - Obesity = Increased weight caused by excess accumulation of fat.
 - "Over-fat" = normal BMI w/large waist
 - · Visceral fat

Slide 17 Slide 18





Slide 19 Slide 20







Slide 21 Slide 22







Slide 23 Slide 24







Slide 25 Slide 26







Slide 27 Slide 28






Slide 29 Slide 30







Slide 31 Slide 32



Step 1: Lifestyle modifications Diet and exercise Limit alcohol and tobacco use Reduce stress factors Step 2: If lifestyle changes are not enough, drug therapy will be introduced Step 3: If previous steps don't work, drug dose or type will be changed or another drug is added Step 4: More medications are added until blood pressure is controlled


Slide 33 Slide 34







Slide 35 Slide 36

Hypoperfusion Retinopathy and the Ocular Ischemic Syndrome





Slide 37 Slide 38






Slide 39 Slide 40





Slide 41 Slide 42

NVI and Cataract in Ocular Ischemic Syndrome





The Ocular Ischemic Syndrome (OIS)

Key Point ▲

 <u>Bilateral</u> involvement in patients with ocular ischemic syndrome may occur in up to <u>~20%</u> of all cases?

Slide 43

The Eye in Systemic Disease

Pathogenesis: Ocular Ischemic Syndrome

Non-invasive Carotid Doppler (Duplex) ultrasound**

 Atheromatous ulceration and stenosis at the bifurcation of the common carotid artery (90% occlusion has to be present).



Slide 44

Key Point

 The most common etiology of ocular ischemic syndrome is severe unilateral or bilateral atherosclerotic disease of the Internal Carotid A. Slide 45 Slide 46

The Eye in Systemic Disease

OIS Work Up:

- · Carotid artery evaluation (Carotid Duplex Scanning)-ICA, ECA, CCA
- · Color Trans-cranial Doppler (TCD) ocular arteries
- · Possible MRA (Magnetic Resonance Angiography)
- · Computed Tomography (CT) Angiography
- Cardiology work up (Echocardiogram) Transesophogeal/Transthoracic
- · HTN, DM, Lipid Panel, ESR, C-reactive protein

The Eye in Sytemic Disease Ocular Ischemic Syndrome Cholesterol Plaques, disc pallor

Slide 47 Slide 48

The Eye in Systemic Disease


Ocular Ischemic Syndrome

Treatment:


- · Consider carotid surgery if warranted (Endarterectomy)
 - European Carotid Surgery Trial (ECST)
 - O North American Symptomatic Carotid End. Trial (NASCET)
- . Therapeutic approach Aspirin (325 mg QD or BID), Plavix
- Control modifiable vascular risk factors (HTN, DM, dyslipidemia)
- · Stop smoking
- · Panretinal photocoagulation (PRP) if neovascularization

**Important Note:

Leading cause of death in OIS = Ischemic heart disease Second leading cause of death = Stroke





Slide 49 Slide 50







Slide 51 Slide 52






Slide 53 Slide 54





Slide 55 Slide 56





Slide 57 Slide 58

HCQ TOXICITY

Perform DFE annually.

What additional testing/work-up is appropriate?

Case 65 Year old Asian Female Comes in with complaints of blurred and dimmed vision PMH: Rheumatoid Arthritis x 15 years OcHx: S/P CE and IOL OU

Slide 59 Slide 60

Ophthalmic Exam

VA:

- OD: 20/60 OS: 20/70


· IOP

- OD: 14 OS: 13


SLE:


-OD: PCIOL OS: PCIOL

DFE:





Slide 61 Slide 62






Slide 63 Slide 64







Slide 65 Slide 66







Slide 67 Slide 68






Slide 69 Slide 70






Slide 71 Slide 72




What is the recommended maximum HCQ dose? Calculate Max Dose in mg/day 2.3 x weight (in lbs.) = Max dose At recommended dose, risk of toxicity is < 1% after 5 years, < 2% after 10 yrs. Risk rises to almost 20% after 20 years. ** Our patient VY (~110-120 lbs) was taking 400 mg/d for 20 yrs Risk for HCQ maculopathy depends on daily dose, duration of use


Slide 73 Slide 74







Slide 75 Slide 76





Slide 77 Slide 78





Slide 79 Slide 80


Plaquenil Maculopathy


- Testing for patients on Plaquenil
 - DFE
 - VF 10-2 W/W (add 24-2 or 30-2 in Asians)
 - SD or SS-OCT: raster and cube scans
 - FAF
 - mfERG
- Increase frequency of monitoring (2+ visits per year) w/degree of pathophysiology.

Summary and Case Outcome

- MMI and other diagnostics are essential in evaluation of patients using CQ or HCQ on a chronic basis.
- Co-management team includes:
 - Optometry
 - Rheumatology
 - Other therapies: methotrexate, TNF inhibitors (our patient VY was switched to this drug class)

Slide 81 Slide 82





Slide 83 Slide 84

What is Sleep Apnea?

- Apnea is defined as complete cessation of breathing for more than 10 seconds.
- SAS is characterized by repeated apneas or periods of shallow breathing during sleep.

Epidemiology

- OSA is most common in overweight or obese men.
- It occurs in approximately 22-24 percent of men and 9-17 percent of women.
- African Americans have a 2.5 times higher risk.

Slide 85 Slide 86

Epidemiology

· OSA occurs in 34 percent of NFL linemen



Types of Sleep Apnea


- Central sleep apnea (CSA)
 - caused by the loss of ventilatory effort controlled by the CNS
 - brain is not properly telling the body when to breathe
 - < 1%
- · Obstructive sleep apnea (OSA)
 - caused by upper airway obstruction or collapse
 - ~85%
- · Mixed sleep apnea (MSA)
 - ~15%
- . The mechanisms underlying these different types of sleep apnea are likely to overlap.*

Slide 87

Slide 88

Obstructive Sleep Apnea

- An average of at least 10 apneic and hypopneic episodes per sleep hour.
- Leads to excessive daytime drowsiness because of marked fragmentation of sleep.



Why should we care?

- Reported ophthalmic findings in patients with SAS include:
 - Floppy eyelid syndrome
 - Glaucoma
 - Keratoconus
 - HR, DR, RVO
 - Central serous chorioretinopathy (CSC)
 - Optic disc edema (IIH and non-IIH)
 - Non-arteritic anterior ischemic optic neuropathy

Slide 89 Slide 90

Who develops SAS/OSA?

- SAS can occur at any age.
- Risk factors include excess weight and obesity, male sex, physical inactivity, upper airway abnormalities (i.e. small airway or enlarged tonsils), alcohol use, loud snoring, family history, allergies, and wide neck girth.



Slide 91 Slide 92

Obesity and SAS



An obese young woman with the short, thick neck as typically seen in SAS.

Ocular Complications of OSA

- · Changes in eyelid tissue
 - Floppy eyelid syndrome (FES)
- · Changes in cornea
 - K-conus
- Changes in the optic nerve
 - The glaucomas
 - · Open angle (OAG)
 - · IOP-independent GLC (NTG) *
 - Non-arteritic anterior ischemic optic neuropathy (NAION)
 - Optic Disc Edema (IIH and non-IIH)
- Changes in retina: DR, HR, RVO, CSC*



Slide 93 Slide 94





Floppy Eyelid Syndrome (FES)

- History: obesity, type 2 DM → suspect OSA
- Treatment/Management
 - CPAP
 - Lubricate
 - Anti-inflamm
 - Antimicrobial
 - Protect eye
 - Bandage CL
 - · AMT
 - Combo Therapy



40 y/o BF +FES, OSA, IIH

Slide 95

Diagnosis/Management of FES

Diagnosis

- · Vital dye staining
- · Abnormally lax upper lid on eversion

Treatment


- · Goal: To protect ocular surface during sleep
 - Topical lubricants
 - Topical antibiotics for mild corneal/conj abnormalities
 - Educate patient to refrain from sleeping face-down
- · Eyelid tightening procedure
 - Horizontal lid shortening

Slide 96

Questions and Answers?



Slide 97 Slide 98




SAS and Type 2 DM

 The ADA recommends that all type 2 patients be screened for OSA, and vice versa.*



Slide 99



Slide 100

Early Diagnosis is Essential!

- OSA and retinal vascular disease have a high cost burden on the healthcare system.
- OSA creates systemic changes and hypoxic conditions that may incite or exacerbate retinal vascular diseases.
- Retinal changes may be the first clinical manifestation of otherwise undiagnosed OSA, so it is important to refer patients with new-onset retinal vascular disease for appropriate sleep testing.

Slide 101 Slide 102






Slide 103 Slide 104

OSA and Weight

- OSA is a sleep disorder that affects an estimated 22% of men and 17% of women globally [1].
- ~75% of individuals with a BMI greater than 40 kg/m² have OSA and that 58% of moderate-to-severe OSA cases are attributable to a BMI greater than or equal to 25 ^[2,3].
- The prevalence of OSA has increased by as much as 55% in certain age groups in the last two decades alone [4].



Slide 105 Slide 106

Does your patient have OSA?

- Snoring marked by frequent changes in loudness and frequency (as opposed to quiet and steady) is highly suggestive.
- Excessive daytime sleepiness/tiredness or fatigue, especially when not active.
- Episodes during sleep when breathing stops.
- Periods of loud snoring followed by silence or a total absence of breathing, lasting from a few seconds up to a minute or longer.

Risk Factors for OSA

- Obesity/excess weight
- · Male sex
- · Upper airway abnormalities
- · Alcohol use
- Snoring
- Neck girth of more than 17 inches in men or 16 inches in women.

Slide 107

Signs and Symptoms

- Loud snoring
- Feeling fatigued in the morning
- Falling asleep during the day
- · Memory loss
- Poor judgment
- Personality changes

Slide 108

Why are there ocular vascular complications?

- The primary drivers of the ocular complications of OSA are intermittent hypoxia, <u>sympathetic</u> system activation, oxidative stress, and adverse effects of endothelin 1 [14].
- Retinal vascular disease has a high economic burden on healthcare systems.
- Diabetic retinopathy alone cost the US health system \$4.5 billion in 2020 [15].


Slide 109 Slide 110


Case: 55 YOHM

5 ft 10 in, 295 lbs Central blur OD/OS Type 2 DM x 3 yrs +OSA, +HTN, +Dyslipidemia



Slide 111 Slide 112





Slide 113 Slide 114

QUESTION:

WHICH FACTORS MOST INFLUENCE THE ONSET, PROGRESSION AND VISUAL OUTCOME OF DIABETIC RETINOPATHY?

Systemic Conditions that May Exacerbate DR Dyslipidemia Hypertension Carotid occlusive dx Kidney disease Sleep apnea Anemia Obesity Vasculitis Neuropathy Nephropathy Vitamin D deficiency

Slide 115 Slide 116


OSA and DM


- The relationship between OSA and diabetes is bidirectional.
- Just as OSA may increase risk of developing diabetes, diabetes is a risk factor for developing OSA.
- During REM sleep, an increased apnea—hypopnea index (AHI)

 the number of apneic and hypoxic events per sleep hour –
 is linked with DR, even when controlling for other risk factors [21].





Slide 117 Slide 118







Slide 119 Slide 120






Slide 121 Slide 122






Slide 123 Slide 124



What is multimodal imaging (MMI)?

- MMI is the use of multiple technological systems to acquire images.
- These may include hybrid devices that can simultaneously perform more than one imaging modality.
- MMI does not replace, but rather it augments, traditional examination methods, such as DFE.


Slide 125 Slide 126




What is the purpose of MMI?


- Images acquired by MMI complement one another for the purpose of diagnosis, prognostication, management, and monitoring of disease.
- Common imaging modalities include:
 - Ocolor/multicolor fundus imaging
 - Onear-infrared reflectance (NIR)
 - Ofundus autofluorescence (FAF)
 - OOCT and OCTA


Slide 127 Slide 128





Slide 129 Slide 130





Slide 131 Slide 132






Slide 133 Slide 134

OSA: Making the Diagnosis

- · Polysomnography
 - Eye movement observations (REM)
 - Electroencephalogram (arousals from sleep)
 - Chest wall monitors (respiratory movements)
 - Electrocardiogram (heart activity)
 - Electromyogram (limb movements)
 - Oximetry (measure oxygen saturation)

Pulse Oximetry





Slide 135 Slide 136

Pulse Oximetry

- Small beams of red/IR light pass through the blood in the finger.
- Measures changes of light absorption in oxygenated or deoxygenated blood.
- The pulse oximeter measures oxygen saturation levels along with heartrate.



Diagnostic Parameters

- · Respiratory disturbance index (RDI)
 - -# of obstructive breathing events (apneas) per hour
 - Used to diagnose and grade the severity of OSA

Slide 137 Slide 138

The Apnea-Hypoapnea Index


- Apneas are strongly associated w/reduced blood oxygen levels.
 - can decrease by up to 4%
- Respiratory effort-related arousal (RERA)
 - This is a breathing disorder characterized by obstructive upper airway (air)flow reduction...
 - ...that does not meet the criteria of an apnea or hypopnea

The Apnea-Hypoapnea Index

- Hypoapneas are events in which there is a decrease, but not a total cessation, of breathing during sleep.
- · To calculate AHI
 - Simply add the total number of events (apneas, RERAs, and hypoapneas)
 - Divide this by the total number of hours slept during the study.


Slide 139 Slide 140

AHI: lower is better




Sleep Apnea and DR/DME DME Higher prevalence Recurrence rate higher Unresponsive to Anti-VEGF PDR Higher prevalence Worsening Improvement of DME, PDR w/CPAP West, S. D., et al. "The prevalence of retinopathy in men with Type 2 diabetes and obstructive sleep apnea." Diabetic Medicine 27.4 (2010): 423-430.

Slide 141 Slide 142




Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

- · Cause
 - Ischemic vascular disease
- Diagnosis
 - Rule out arteritic!
- · Treatment/management
 - Systemic



Slide 143





Slide 144

NAION Pathophysiology


- Alteration of the blood supply to the optic nerve head
 - Ischemic process affecting the SPCAs
 - As the ischemic episode evolves, disc swelling (edema) compromises circulation, leading to further neuronal damage.
- Common etiologies of NAION include CV Dx, DM, arteriolar sclerosis, OSA.*

Slide 145 Slide 146





Slide 147 Slide 148




SAS and Systemic Disease

- Systemic arterial hypertension present in ~50% of OSA cases.
- · Congestive heart failure
- · Pulmonary hypertension
- Stroke
 - OSA is an independent Risk Factor*
- · Metabolic syndrome
- · Type 2 diabetes mellitus

Slide 149 Slide 150

Diabesity


- M S is characterized by central (abdominal) obesity, dyslipidemia, raised blood pressure, and insulin resistance.
- "Diabesity"
 - Up to 97% of type 2 caused by excessive weight
 - Obesity = Increased weight caused by excess accumulation of fat.
 - "Over-fat" = normal BMI w/large waist
 - · Visceral fat




Slide 151


The Pathology of Obesity Yeast Infections, Gout Skin Endocrine Polycystic Ovarian Syndrome, Low Testosterone, High Estrogen Heart Attack, Stroke, CHF Heart Pulmonary Sleep Apnea Gallstones, GERD Urinary Incontinence Gyno Abnormal Menses, Infertility Depression, Memory Problems Neuro CANCER Breast, Colon, Prostate, Bladder, Esophagus Cancer Pulmonary Embolism Post-Op

Slide 152




Slide 153 Slide 154






Slide 155



Slide 156




Slide 157 Slide 158







Slide 159



Slide 160



Slide 161 Slide 162






Slide 163 Slide 164




Obesity and Body Mass Index (BMI)


- World Health Organization (WHO) Classification
 - For adults, Grade 1 (simply called overweight) is a BMI of 25-29.9 kg/m2.
 - Grade 2 (commonly called obesity) is a BMI of 30-39.9 kg/m2.
 - Grade 3 (commonly called severe obesity) is a BMI greater than or equal to 40 kg/m2.


Slide 165 Slide 166





Slide 167 Slide 168





Slide 169 Slide 170



Management of OSA

- · Weight loss
 - Start with 5%
- · Continuous positive airway pressure (CPAP)
 - Blows air into nostrils
- · BiPAP therapy
- · Oral appliances
 - Tongue retained devices
 - Bring lower jaw forward
- · Uvulopalatopharyngoplasty (UPPP)
 - Surgical removal of anatomic obstructions

Slide 171

CPAP Therapy When the company of th

Slide 172

BiPAP Therapy



- Main difference is that BiPAPs have 2 pressure settings: a prescribed pressure for inhalation (ipap), and a lower pressure for exhalation (epap).
- Dual settings allow the patient to get more air in and out of their lungs, making it easier to breathe during sleep.

Slide 173 Slide 174

Tongue Retaining Device



Oral Appliances




The OA fits like a sports mouth guard or an orthodontic retainer. It supports the jaw in a forward position to help maintain an open upper airway.

Slide 175



UPPP Surgery





Slide 176


Treatment and Management of SAS

- Patients in whom non-invasive therapy (e.g. CPAP, BiPAP, OAs) fails may be offered surgical options.
 - Patient should be made aware of the success rates for each surgical procedure.
 - Inform them that they might require more than one procedure, some fairly extensive.
 - Refer patients only to centers that have personnel experienced in these special surgical techniques

Slide 177 Slide 178







Slide 179


Treatment

- Proper treatment of OSA with continuous positive airway pressure (CPAP) therapy has been shown to improve visual sensitivity as well as RNFL thickness [16,17].
- It is essential to recognize the link between these disorders and OSA not only for the preservation of visual function...
- ...but also for proper treatment of OSA, and thus mitigation of the variety of morbidity and mortality because of uncontrolled, undiagnosed OSA.

Slide 180

Questions and Answers

IIH + OSA



AUDIENCE


Slide 181 Slide 182




Co-manage Uveal Melanoma with:

Retina/Ocular Oncology PCP General Oncology

Slide 183 Slide 184





Slide 185 Slide 186



Collaborative Ocular Melanoma Study

- . Organized and funded in 1985 to address issues related to management of choroidal melanoma.
- · Main Outcome: overall survival of patient following treatment
- . > 4000 patients. 65% pts eligible

< 2.5 mm in height Small melanomas Medium melanomas 2.5 - 10.0 mm Large melanomas > 10.0 mm

Secondary outcomes: metastasis-free survival, # years of useful vision.

Brachytherapy for Uveal Melanoma

- · Plaque left in place for 4 days to provide 8,000 centigray of radiation to entire tumor.
- · The remainder of the body receives a small amount of radiation, about the equivalent of a chest x-ray.





Slide 187

Treatment Side Effects

- · Main side effect of focal · Radiation retinopathy! ocular treatment is...




- NVD / NVE
- · Exudative changes
- Macular edema
- · Occurs several weeks to months after therapy

Slide 188


Choroidal melanomapre-Radiotherapy







Acknowledgement: Brad Sutton, OD

Slide 189 Slide 190





Slide 191 Slide 192






Slide 193 Slide 194

Management of RR

- · Avastin/Lucentis/Eylea
- Laser
- · Silicone oil at time of Brachytherapy
 - attenuates radiation dose, may protect against RR






Slide 195 Slide 196


Melanoma Metastasis

Risk factors for metastasis from the choroid:

- Thickness > 2 mm
- Symptoms Flashes, floaters, loss of vision
- · Proximity to the optic nerve
- · Documented growth

Shields CI Shields JA. Risk factors for metastasis of small choriodal melanocytic Lesions. Ophthalmology 1995





Slide 197 Slide 198

Ocular Melanoma Quiz

- What is the 10-year mortality rate for patients diagnosed with a uveal melanoma?
- a. 1 %
- b. 7%
- c. 9%
- d. 50%

Ocular Melanoma Quiz

- What is the 10-year mortality rate for patients diagnosed with a uveal melanoma?
- a. 1 %
- b. 7%
- c. 9%
- d. 50%

Slide 199

Slide 200

Conclusion

ror of


Thank you for spending your precious time with me!


• Joe

Slide 201 Slide 202

Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

- Cause
 - Ischemic vascular disease
- Diagnosis
 - Rule out arteritic!
- · Treatment/management
 - Systemic






Slide 203 Slide 204


NAION Pathophysiology

- Alteration of the blood supply to the optic nerve head
 - Ischemic process affecting the SPCAs
 - As the ischemic episode evolves, disc swelling (edema) compromises circulation, leading to further neuronal damage.
- Common etiologies of NAION include CV Dx, DM, arteriolar sclerosis, <u>OSA.*</u>




Slide 205 Slide 206

S/P NAION Showing Sector Disc Pallor in NA-AION



Visual Field Testing in OSA



Altitudinal defect in NAION

Slide 207 Slide 208

Keratoconus

- · Diagnosis is clinical
 - Traditional and special diagnostic testing
- The FES has been linked with both OSA and keratoconus in several studies.*
- · Obesity and KC
- · Treatment/management of KC

SAS and the Eye

- Marfan's Syndrome-related Complications (facial anomalies)
 - Ectopia lentis
 - decentered crystalline lens, secondary to disruption of surrounding zonular fibers
- Patients with ectopia lentis are at an increased risk for retinal detachment

Slide 209 Slide 210

SAS and Systemic Disease

- Half of all patients living with essential hypertension also have OSA.
- Likewise, half of patients who have OSA also have essential hypertension.
- Therefore, OSA appears to be a contributing factor in the development of essential hypertension.


SAS and Systemic Disease

- Systemic arterial hypertension present in ~50% of OSA cases.
- · Congestive heart failure
- · Pulmonary hypertension
- Stroke
 - OSA is an independent Risk Factor*
- · Metabolic syndrome
- · Type 2 diabetes mellitus


Slide 211 Slide 212


Diabesity

- M_____S___ is characterized by central (abdominal) obesity, dyslipidemia, raised blood pressure, and insulin resistance.
- "Diabesity"
 - Up to 97% of type 2 caused by excessive weight
 - Obesity = Increased weight caused by excess accumulation of fat.
 - "Over-fat" = normal BMI w/large waist
 - · Visceral fat





Slide 213 Slide 214






Slide 215 Slide 216







Slide 217 Slide 218






Slide 219 Slide 220







Slide 221 Slide 222

Now what?

- ODs should refer patients with these ocular findings for a sleep study, particularly if patient fits the OSA demographic profile or complains of sleep disturbances.
- Similarly, sleep medicine specialists should recommend that all their patients have a thorough ocular health examination.
- More cross-referrals support better outcomes for our patients.




Slide 223 Slide 224

Treatment

- Proper treatment of OSA with continuous positive airway pressure (CPAP) therapy has been shown to improve visual sensitivity as well as RNFL thickness [16,17].
- It is essential to recognize the link between these disorders and OSA not only for the preservation of visual function...
- ...but also for proper treatment of OSA, and thus mitigation of the variety of morbidity and mortality because of uncontrolled, undiagnosed OSA.

Questions and Answers

IIH + OSA



AUDIENCE

